Serotonin augmentation therapy by escitalopram has minimal effects on amyloid-β levels in early-stage Alzheimer’s-like disease in mice

Serotonin augmentation therapy by escitalopram has minimal effects on amyloid-β levels in early-stage Alzheimer’s-like disease in mice

Abstract Background Dysfunction of the serotonergic (5-HTergic) system has been implicated in the cognitive and behavioural symptoms of Alzheimer’s disease (AD). Accumulation of toxic amyloid-β (Aβ) species is a hallmark of AD and an instigator of pathology. Serotonin (5-HT) augmentation therapy by...

Full description

Bibliographic Details
Main Authors: Christian Ulrich von Linstow, Jonas Waider, Manuela Grebing, Athanasios Metaxas, Klaus Peter Lesch, Bente Finsen
Format: Article
Language:English
Published: BMC 2017-09-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s disease
APP/PS1
Cerebral amyloidosis
5-HT
SSRI
5,7-Dihydroxytryptamine
Online Access:http://link.springer.com/article/10.1186/s13195-017-0298-y

Internet

http://link.springer.com/article/10.1186/s13195-017-0298-y

Similar Items